Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,645 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,645 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05337735 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare… | Phase 2 | suspended | Apr 20, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05815160 | Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small… | Phase 1 | terminated | Apr 18, 2023 | Debiopharm International SA | The trial was concluded for strategic reasons. | Sponsor / business decision |
| NCT06192004 | Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and…(LOOP) | — | terminated | Jan 5, 2024 | AstraZeneca | Observed event rate was below the rate required to meet study objectives. | Other (stated, no rule matched) |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT06732258 | Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab… | Phase 1 | withdrawn | Dec 13, 2024 | Sichuan University | Inorder to avoid the serious adverse effect of Toripalimab combining with Tifcemalimab, considering… | Safety / toxicity |
| NCT06897579 | Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With… | Phase 2 | terminated | Mar 27, 2025 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate… | Phase 1 / Phase 2 | withdrawn | Jan 9, 2026 | National Cancer Institute (NCI) | Study drug supplier withdrew support; no participants were enrolled. | Enrollment / accrual |
| NCT06235242 | GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With… | N/A | terminated | Jan 31, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06513663 | Exercise as Maintenance Therapy in Advanced Lung Cancer | N/A | terminated | Jul 22, 2024 | Indiana University | trial stopped due to low accrual | Enrollment / accrual |
| NCT06519669 | Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With… | N/A | terminated | Jul 25, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06572722 | Perioperative Immunotherapy for NSCLC (ECTOP-1030) | Phase 2 | withdrawn | Aug 27, 2024 | Fudan University | This trial has not been initiated | Other (stated, no rule matched) |
| NCT03737994 | Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for… | Phase 2 | terminated | Nov 13, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With…(PANDA-VAC) | Phase 1 | suspended | Feb 12, 2020 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients… | Phase 1 | terminated | Jul 9, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or… | Phase 1 | terminated | May 16, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT02257619 | Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung… | Phase 2 | terminated | Oct 6, 2014 | Incyte Corporation | Sponsor decision to not initiate part 2 due to slow enrollment and competing trials. | Enrollment / accrual |
| NCT02298153 | A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously… | Phase 1 | terminated | Nov 21, 2014 | Incyte Corporation | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04638582 | Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung… | Phase 2 | terminated | Nov 20, 2020 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Study was terminated due to low recruitment. | Enrollment / accrual |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT05397093 | ITIL-306 in Advanced Solid Tumors | Phase 1 | terminated | May 31, 2022 | Instil Bio | The study was terminated early due to discontinuation of development of the investigational program | Other (stated, no rule matched) |
| NCT00280189 | Study of Outcomes of Radiofrequency Ablation of Lung Tumors | — | suspended | Jan 20, 2006 | University of Pittsburgh | not stated | Not stated |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll… | Phase 1 / Phase 2 | terminated | May 6, 2016 | Cancer Trials Ireland | Accrual lower than anticipated and not expected to improve | Enrollment / accrual |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or… | Phase 2 | terminated | Jun 11, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT06836414 | Lung Cancer Screening CT for Firefighters | N/A | withdrawn | Feb 20, 2025 | University of California, San Francisco | Funding | Funding |
| NCT06130254 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the… | Phase 1 | terminated | Nov 14, 2023 | M.D. Anderson Cancer Center | Sponsor discontinued the trial | Other (stated, no rule matched) |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Phase 1 | terminated | May 19, 2021 | Deciphera Pharmaceuticals, LLC | Trial terminated due to business decision, not based on any safety or efficacy concerns. | Safety / toxicity |
| NCT06434103 | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without… | Phase 1 / Phase 2 | withdrawn | May 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor's Strategy Adjustment | Sponsor / business decision |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced…(PIPSeN) | Phase 2 | terminated | Feb 11, 2016 | Gustave Roussy, Cancer Campus, Grand Paris | study design, change of standard of care, enrollment difficulties | Enrollment / accrual |
| NCT04908111 | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Phase 1 / Phase 2 | suspended | Jun 1, 2021 | Cancer Research UK | Sponsor has decided to permanently close recruitment | Enrollment / accrual |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage… | Early Phase 1 | terminated | Nov 21, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | Phase 1 | terminated | Mar 13, 2023 | Taiho Oncology, Inc. | Sponsor's decision, not based on safety concerns | Safety / toxicity |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in… | Phase 1 / Phase 2 | terminated | Dec 29, 2023 | Therapex Co., Ltd | Sponsor's decision | Sponsor / business decision |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung… | Phase 1 | terminated | Jun 16, 2020 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small… | Phase 1 | terminated | Jun 2, 2021 | The Methodist Hospital Research Institute | Poor accrual | Enrollment / accrual |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06713798 | Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures(INDIGO) | Phase 2 | withdrawn | Dec 3, 2024 | Gustave Roussy, Cancer Campus, Grand Paris | Roche stopped thr peoduction of one of the study product. | Other (stated, no rule matched) |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT03265496 | Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive…(CONCORDE) | N/A | terminated | Aug 29, 2017 | Centre Oscar Lambret | The number of recruted patient was not sufficient | Other (stated, no rule matched) |
| NCT06083454 | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Oct 16, 2023 | William Zeitler | funding change | Funding |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line… | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Xencor, Inc. | Business Decision | Sponsor / business decision |
| NCT04832854 | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus… | Phase 2 | terminated | Apr 6, 2021 | Hoffmann-La Roche | Study was terminated as data became available from Phase 3 trials of perioperative regimens… | Efficacy / futility |
| NCT05636267 | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | Phase 1 / Phase 2 | terminated | Dec 5, 2022 | Akeso | Terminated due to sponsor strategic development reprioritization. | Sponsor / business decision |
| NCT06219174 | Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC… | Phase 1 / Phase 2 | suspended | Jan 23, 2024 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable | Other (stated, no rule matched) |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced…(AcceleRET-Lung) | Phase 3 | terminated | Jan 10, 2020 | Hoffmann-La Roche | Early termination of the study resulted from organizational and commercial decisions that led to… | Other (stated, no rule matched) |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT04880382 | Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration…(OPTIMUNELUNG) | Phase 2 | terminated | May 10, 2021 | Institut Bergonié | Enrolment was slowlier than expected. | Enrollment / accrual |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06315296 | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing… | N/A | terminated | Mar 18, 2024 | Thomas Jefferson University | slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 4, 2026source: clinicaltrials